Übersicht			Auf mobile öffnen

Lieferstatus:	Auf Bestellung (Lieferzeit unbekannt)
Veröffentlichung:	September 2018
Genre:	Schulbücher
	adaptive trial design / clinical trial methodology / Epidemiology & medical statistics / Epidemiology and Medical statistics / evidence quantification / MATHEMATICS / Probability & Statistics / General / MEDICAL / Biostatistics / MEDICAL / Epidemiology / Pharmaceutical chemistry and technology / Pharmaceutical Statistics / Pharmaceutical technology / Probability & statistics / Probability and statistics / quantitative drug development strategies / regulatory decision making / survival analysis methods / TECHNOLOGY & ENGINEERING / Pharmaceutical mehr...
ISBN:	9781138374683
EAN-Code:	9781138374683
Verlag:	Taylor and Francis
Einband:	Kartoniert
Sprache:	English
Serie:	Chapman & Hall/CRC Biostatistics Series
Dimensionen:	H 234 mm / B 156 mm / D
Gewicht:	490 gr
Seiten:	261
Illustration:	schwarz-weiss Illustrationen, Tabellen, schwarz-weiss
Bewertung:	Titel bewerten / Meinung schreiben

Inhalt:

This book focuses on the efficient development of drugs and the quantification of evidence in drug development. It presents a formal quantitative framework for understanding drug development that goes beyond simply describing the properties of the statistics in individual studies. Examining the drug development process from the perspectives of both drug companies and regulatory agencies, the author provides a rationale for underpowered phase 2 trials based on the notion of efficiency and develops a framework for evaluating the strength of evidence generated by clinical trials.